newsfilter
← Latest News
PR Newswire·

Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US

Companies collaborating to expand access to TZIELD™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes RED BANK, N.J., Feb. 13, 2023 /PRNewswire/ -- Provention Bio, Inc.